NASDAQ:IMMP Prima BioMed (IMMP) Stock Price, News & Analysis $0.38 +0.00 (+0.80%) Closing price 04:00 PM EasternExtended Trading$0.38 0.00 (-0.32%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainSEC FilingsTrendsBuy This Stock About Prima BioMed Stock (NASDAQ:IMMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prima BioMed alerts:Sign Up Key Stats Today's Range$0.37▼$0.3850-Day Range$0.31▼$0.6252-Week Range$0.29▼$3.53Volume338,760 shsAverage Volume8.17 million shsMarket Capitalization$55.59 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingHold Company Overview Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response. This candidate is being evaluated in multiple Phase II clinical trials across a range of solid tumors, including breast and lung cancers. Founded in 2001 and headquartered in Sydney, Australia, Prima BioMed has built its expertise in immuno-oncology over two decades of research and development. In 2018, the company rebranded as Immutep to reflect its broader strategic focus on LAG-3–based immunotherapies. Since its inception, Prima BioMed has collaborated with leading academic institutions and cancer centers worldwide to advance its clinical programs and validate the therapeutic potential of LAG-3 modulation. Prima BioMed maintains a global footprint with additional offices and research partnerships in Europe and the United States. Through collaborations with pharmaceutical partners and contract research organizations, the company aims to accelerate clinical development, streamline regulatory submissions and establish a foundation for potential commercialization. Its pipeline also includes monoclonal antibodies targeting LAG-3 and other immune checkpoints, underscoring a commitment to expanding treatment options for patients with hard-to-treat malignancies.AI Generated. May Contain Errors. Read More Prima BioMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreIMMP MarketRank™: Prima BioMed scored higher than 49% of companies evaluated by MarketBeat, and ranked 481st out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPrima BioMed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialPrima BioMed has a consensus price target of $5.50, representing about 1,374.5% upside from its current price of $0.37.Amount of Analyst CoveragePrima BioMed has only been the subject of 1 research reports in the past 90 days.Read more about Prima BioMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPrima BioMed has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Prima BioMed's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.04% of the float of Prima BioMed has been sold short.Short Interest Ratio / Days to CoverPrima BioMed has a short interest ratio ("days to cover") of 4.23.Change versus previous monthShort interest in Prima BioMed has recently decreased by 15.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrima BioMed does not currently pay a dividend.Dividend GrowthPrima BioMed does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.18 News SentimentPrima BioMed has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Prima BioMed this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for IMMP on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Prima BioMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prima BioMed insiders have not sold or bought any company stock.Percentage Held by Insiders3.07% of the stock of Prima BioMed is held by insiders.Percentage Held by Institutions2.32% of the stock of Prima BioMed is held by institutions.Read more about Prima BioMed's insider trading history. Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prima BioMed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMMP Stock News HeadlinesIMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmJune 22 at 4:05 AM | prnewswire.comImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMPJune 22 at 4:00 AM | prnewswire.comElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon Musk has been quietly doubling down on it, even attempting to deploy it during his time at DOGE before being shut down. Investing legend Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - has spent six years analyzing this sector he calls 'W.T.E.' He believes it could be 90 times bigger than AI and 1,900 times bigger than Bitcoin.June 22 at 1:00 AM | Brownstone Research (Ad)INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMPJune 18, 2026 | prnewswire.comIMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmJune 18, 2026 | globenewswire.comIMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces DeadlineJune 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMPJune 16, 2026 | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Immutep Limited InvestorsJune 16, 2026 | globenewswire.comSee More Headlines IMMP Stock Analysis - Frequently Asked Questions How have IMMP shares performed this year? Prima BioMed's stock was trading at $2.86 at the beginning of the year. Since then, IMMP stock has decreased by 87.0% and is now trading at $0.3730. How do I buy shares of Prima BioMed? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prima BioMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prima BioMed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Pfizer (PFE), Broadcom (AVGO) and GE Aerospace (GE). Company Calendar Today6/22/2026Fiscal Year End6/30/2026Next Earnings (Estimated)9/02/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 3 weeks, IMMP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMMP CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year Founded2001Price Target and Rating Average Price Target for Prima BioMed$5.50 High Price Target$10.00 Low Price Target$1.00 Potential Upside/Downside+1,358.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick RatioN/A Sales & Book Value Annual Sales$6.69 million Price / Sales8.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.60Miscellaneous Outstanding Shares147,370,000Free Float142,848,000Market Cap$55.59 million OptionableOptionable Beta2.21 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IMMP) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersBofA: Digital Dollar Coming 2025-2030The US government has ONLY ONE mathematical escape from $38.4T in debt: explosive AI-driven GDP growth. AI ...Decentralized Masters | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calli...Awesomely, LLC | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
